CASCADE-LUNG: Cancer Screening Assay using DELFI; A Clinical Validation Study in Lung

Date Added
May 23rd, 2022
PRO Number
Pro00119559
Researcher
Gerard Silvestri

List of Studies


Keywords
Cancer/Lung, Lung
Summary

The purpose of this study is to collect blood samples to determine the ability of a blood-based test that can be used able to identify lung cancers that may or may not also be seen on images of lungs.

Institution
MUSC
Recruitment Contact
Michael Balassone
843-792-6696
Balassom@musc.edu

Safety and Tolerability of Allogeneic Umbilical Cord Derived Mesenchmal Stromal Cells (UC-MSCs) to Limit COVID associated ComplicatioNs: An open label, phase 1 study in hospitalized patients (SAMPSON-1)

Date Added
April 12th, 2022
PRO Number
Pro00115966
Researcher
Charlie Strange

List of Studies


Keywords
Coronavirus, Lung
Summary

COVID-19 Pneumonia is a viral pneumonia caused by the SARS-CoV-2 virus.
Umbilical cord derived mesencymal stromal cells (MSCs) are a form of stem cell (special human cells that are able to develop into many different cells types) that is derived from the placenta of a mother who has had a Caeserian Section. These cells are believed to suppress the body's immune response to the virus by changing the circulating inflammatory cells in the bloodstream. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia illness will be given 2 doses of MSCs at days 1 and 3 after consent. These MSC cells will be administered into a vein in your arm through an intravenous line and safety will be tested. How much oxygen a patient needs will be recorded over 90 days.

Institution
MUSC
Recruitment Contact
Charlie Strange
8437923174
strangec@musc.edu

CONNECTS Master for Clinical Trials targeting macro-, micro-immunothombosis, vascular hyperinflammation, and hypercoagulability and rein-angiotensin-aldosterone system (RAAS) in hospitalized patients with COVID-19 (ACTIV-4 Host Tissue)

Date Added
March 24th, 2022
PRO Number
Pro00114224
Researcher
Andrew Goodwin

List of Studies


Keywords
Coronavirus, Infectious Diseases, Lung, Pulmonary
Summary

The overarching goal of the Master Protocol is to find effective strategies for inpatient management of patients with COVID-19. Therapeutic goals for patients hospitalized for COVID-19 include hastening recovery and preventing progression to critical illness, multiorgan failure, or death. Our objective is to determine whether modulating the host tissue response with agents targeting the RAAS improves clinical outcomes among patients with COVID-19.
Potential agents to investigate on this platform include TXA127 and TRV027. Both have potential beneficial effects on the RAAS system in COVID-19. We postulate that SARS-CoV-2 spike protein interaction with the ACE2 receptor leads to unchecked activity of AngII, and RAAS-targeting therapies will counterbalance pathologic RAAS effects. We will evaluate the efficacy of TXA127 and TRV027 in restoring RAAS balance.

Institution
MUSC
Recruitment Contact
Nadine O'Connor
843-792-1221
oconnorn@musc.edu